Skip to main content
Premium Trial:

Request an Annual Quote

Merck Serono, Caprotec Collaborate on Protein Research

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics said today that it will collaborate with a division of Merck KGaA to identify protein and drug interactions using its mass spectrometry technology.
 
Under the agreement, Caprotec will use its Capture Compound Mass Spectrometry technology for a research project for Merck Serono. Berlin-based Caprotec will be paid research fees and milestone payments for product development, it said.
 
The firm’s CCMS technology consists of small, tri-functional molecules that allow researchers to isolate proteins directly from biological samples that may then be isolated and characterized. The technology can be used in proteomics, drug development, and biomarker research, the company said.
 
Financial terms of the agreement were not released.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.